Evonik Tumbles 18% as BASF Walks Away From €11.2B Takeover Pursuit
Evonik shares tumbled 18% after BASF abandoned its €11.2B takeover bid, walking away over board resistance and prioritizing strict capital discipline.

Shares of German specialty chemicals producer Evonik plummeted 17.7% on Thursday morning after rival BASF officially abandoned its €11.2 billion ($12.3 billion) takeover pursuit. The abrupt collapse of talks strips away a generous €24-per-share premium, leaving Evonik investors exposed to standalone turnaround headwinds across a beleaguered European chemicals landscape.
What happened
German chemicals heavyweight BASF SE confirmed on Thursday, Nov. 19, that it had formally terminated all discussions regarding an all-cash acquisition of Evonik Industries AG. The decision follows the rejection of two non-binding proposals by Evonik’s Executive Board, capped by a sweetened €24-per-share offer that valued the Essen-based specialty group at approximately €11.18 billion.
BASF Chief Executive Markus Kamieth stated that despite signaling flexibility for a moderate bump, Evonik failed to show meaningful engagement. Pushing beyond €24 would fail to serve BASF shareholders, Kamieth affirmed, triggering a swift withdrawal under BASF’s 'Winning Ways' strategy.
Market reaction on Xetra was immediate. Evonik plunged 17.7%, erasing nearly €2 billion in market capitalisation as speculative takeover premia evaporated. In contrast, BASF shares edged up roughly 0.5%, reflecting relief among Ludwigshafen investors that management avoided an expensive bidding war.
Why it matters
For Evonik, independence comes with immediate operational pressure. Without BASF’s deep balance sheet and industrial scale, Evonik must navigate high domestic energy expenses, subdued European demand, and ongoing restructuring alone. Key stakeholders—most notably the RAG-Stiftung, which controls a 43.8% anchor stake, alongside North Rhine-Westphalia political officials—resisted the tie-up to safeguard regional sites and autonomy. Yet thwarting the bid now places the burden solely on Evonik's standalone execution and cost programs.
For BASF, walking away reinforces the capital discipline pledged in its corporate overhaul. Kamieth has repeatedly described major M&A as an option rather than an imperative. By refusing to overpay when facing board resistance and macroeconomic softness, BASF protects its credit metrics and dividend capacity while shifting attention back to core portfolio pruning in a challenging chemical sector cycle.
What to watch next
- Evonik Standalone Targets: Management's timeline for operational cost cuts under its 'Evonik Tailor Made' restructuring plan and upcoming quarterly volume trajectory.
- RAG-Stiftung Strategy: Any shift in stance from Evonik’s 43.8% anchor foundation regarding long-term dividend dependencies and structural options.
- BASF Capital Allocation: Updates on core asset spin-offs, share buybacks, and dividend guidance under the 'Winning Ways' framework.
- European Chemical Demand: Pricing power and margin recovery signals amid stubborn energy costs and global competition.
Stocks in this analysis
AI stock analysis- P/E
- 58.9
- Fwd P/E
- 14.2
- Analyst target (avg)
- €19.55 (−10%)
- P/E
- 22.8
- Fwd P/E
- 16.4
- Analyst target (avg)
- €53.36 (+4%)
Free on aktienanalyse.ai: score profile, ratios versus the industry and business model. Plus, if you want it, the full analysis with fair value and bull, base and bear case. Prices and ratios as of Nov 18, 2026.
This analysis is for information only and is not investment advice. Prices and figures as of publication.